Skip to main content
OpenTrials
Completed

NCT Number: NCT00484549

Fabry : National Initiative of Screening

Fabry disease is a genetic disease due to an enzymatic deficit. A screening of this disease allows patients to benefit from an enzyme replacement therapy and prevent the occurrence of life threatening manifestations such as an ischemic stroke.

The purpose of the study is to determinate the prevalence of Fabry disease in a population of male patients hospitalized for an ischemic stroke.

This study, with a screening of Fabry disease, allows the patients to make a precise diagnosis of their ischemic stroke and to facilitate the screening of the other members at the facility.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ischemic Stroke Hospitalized Brain Diseases Brain Diseases, Metabolic Brain Diseases, Metabolic, Inborn Cardiovascular Diseases Central Nervous System Diseases Cerebral Small Vessel Diseases Cerebrovascular Disorders Congenital, Hereditary, and Neonatal Diseases and Abnormalities Fabry Disease Genetic Diseases, Inborn Genetic Diseases, X-Linked Ischemic Stroke Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Lipidoses Lysosomal Storage Diseases Lysosomal Storage Diseases, Nervous System Metabolic Diseases Metabolism, Inborn Errors Nervous System Diseases Nutritional and Metabolic Diseases Sphingolipidoses Stroke Vascular Diseases

Age range

28 day–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Gabriel Montpied

Clermont-Ferrand, 63003, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hospitalized ischemic stroke
  • Written and signed informed consent from patient or legal representative

Exclusion criteria

  • Patients belonging to a family which has a Fabry disease's diagnosis confirmed

Treatment and study plan

Blood sample

Procedure

Ischemic stroke hospitalized

Primary outcomes

  1. Fabry disease's screening (Positive microdosage confirmed by a macrodosage)

    Time frame: Positive microdosage confirmed by a macrodosage

Secondary outcomes

  1. Describe and compare the characteristics of patients affected by Fabry disease and patients who are not affected Identify clinical and neuroradiological predictive elements of Fabry disease

    Time frame: patients affected by Fabry disease

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Official study title

National, Multicenter, Prospective Study of Screening of Fabry Disease in a Population of Men Over 28 Days Old and Less Than 55 Years, Hospitalized for an Ischemic Stroke.

Acronym: FIND

Important dates

Study start
2007
Primary completion
2008
Study completion
2009
First posted
Jun 11, 2007
Registry last updated
Dec 21, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.